Bayforest Capital’s AnaptysBio ANAB Stock Holding History

Bayforest Capital’s Portfolio ANAB Stock Details ANAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-5,244	Closed	-$291K	–	948
2026 Q1	$291K	Buy	+5,244	New	+$282K	0.33%	41

Other funds holding ANAB

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Bayforest Capital's ANAB Position: Q2 2026 in Review

Bayforest Capital sold out of AnaptysBio (ANAB) in Q2 2026, closing a stake of 5,244 shares — an estimated $291K sold.

Bayforest Capital first reported a position in ANAB in Q1 2026 and held it in 1 quarter. The position peaked at $291K in Q1 2026. 214 funds tracked by Wall St. Rank hold ANAB as of Q2 2026.

Bayforest Capital reported no remaining AnaptysBio position as of Q2 2026 after selling out during the quarter.
Bayforest Capital sold 5,244 AnaptysBio shares in Q2 2026, an estimated $291K.
Bayforest Capital first reported a position in AnaptysBio in Q1 2026 and held it in 1 quarter.
Bayforest Capital's AnaptysBio position peaked at $291K in Q1 2026.
214 funds tracked by Wall St. Rank held AnaptysBio as of Q2 2026.

Based on Bayforest Capital's 13F filing for Q2 2026, filed 5 Aug 2026.